Objective: The purpose of this study was to evaluate the short-term and long-term results of simultaneous surgical treatment of coexisting abdominal aortic aneurysm and bladder carcinoma. Methods: A prospective study was carried out to compare patients undergoing simultaneous surgical treatment of abdominal aneurysm and bladder carcinoma with control patients undergoing surgery for either one of the two diseases alone. From January 1995 to December 2000, 16 consecutive patients were seen with concomitant abdominal aortic aneurysm and bladder carcinoma at our institutional referral center. All patients underwent a standard operative protocol that included aneurysm graft replacement, radical cystoprostatectomy, and urinary reconstruction. Endovascular treatment of the aneurysm was considered in the last 2 years of the study. After each simultaneous treatment case, two control patients were selected according to the same type of vascular or urinary procedure, respectively, and pathologic staging. The analyzed endpoint was mortality, and confounder variables included common and disease-specific risk factors. Frequencies of vascular, urologic, and systemic complications were carefully considered with special attention to graft infection and tumor recurrence. .19) . Cox proportional hazard model results proved no influence of the different group treatments on survival (P ‫؍‬ .49) and no influence of age and risk factors, except for preoperative renal status (P ‫؍‬ .015). The increased mortality rate of the simultaneous treatment group could be ascribed to the presence of preoperative moderate renal insufficiency in two study group patients. Long-term survival of treated patients is mainly dependent on cancer progression. Graft infection and other vascular complications were not observed. Systemic and urologic complications were similar in study and control groups. Conclusion: This study shows that the simultaneous surgical approach to coexisting abdominal aortic aneurysm and transitional cell carcinoma of the bladder represents a suitable choice of treatment in highly specialized centers, but patients with preoperative renal insufficiency should be carefully evaluated. Endovascular treatment represents an appealing alternative whenever indicated. (J Vasc Surg 2003;37:607-14.)
The frequency of both abdominal aortic aneurysm (AAA) and visceral malignant disease increases with advancing age. At the time of AAA reconstruction, the chance to encounter intra-abdominal malignant disease has been found in up to 4% of patients. 1 Surgical treatment of the two potentially life-threatening conditions still represents the best option in many instances, but the best timing of intervention is controversial. The main concern is that aneurysm repair performed simultaneously with other major nonvascular procedures, involving potentially infected body fluids, would increases the risk of graft infection. The staged procedure is not without risk either, necessitating a second anesthesia, major surgery in a complex cicatricial territory, and the delay of definitive therapy of one of two potentially life-threatening diseases. Technical complications are particularly challenging in the staged management of AAA and invasive carcinoma of the bladder. A major urologic resection and possible bladder reconstruction or AAA resection is undertaken in an abdomen obliterated by the first-stage treatment of either disease. Transperitoneal AAA repair after bladder resection and ileal-bladder reconstruction proved to be extremely complex in four patients of our earlier experience. Retroperitoneal approach to AAA repair after surgical transitional cell carcinoma of the bladder (TCCB) treatment could have the advantage of being better tolerated by the patients, with avoidance of the risks of intraperitoneal adhesions. However, because of the retroperitoneal fibrosis and possible adhesions between the aneurysm wall and the ileal-bladder reconstruction, access to distal common iliac vessels could prove equally treacherous in the retroperitoneal approach. Therefore, the staged approach was not considered a fair choice for patients with coexisting diseases, and a standard collaborative protocol was devised to simultaneously treat all patients with AAA and TCCB. A prospective study was undertaken to examine whether the results of the combined approach were not significantly worse than treatment of either disease alone. Mortality and morbidity rates of simultaneously treated patients were compared with control matched patients undergoing surgery for either AAA or TCCB as individual procedures.
MATERIALS AND METHODS
From January 1995 to December 2000, 527 patients underwent AAA graft replacement and 530 patients underwent radical cystoprostatectomy for a TCCB. Sixteen consecutive patients (3%) had concomitant AAA and TCCB and underwent simultaneous surgical treatment.
Indications for surgery included aneurysm size exceeding 4.5 cm, whenever the diameter ratio between AAA and proximal native aorta was greater than 2, and clinical TCCB stage of T 2 or more without metastases. Beginning in January 1999, patients with concomitant AAA and TCCB were evaluated for the endovascular treatment of AAA. Clinical TCCB stage of less than T 2 was considered for bladder resection if the disease was nonresponsive to repeated cycles of local immunotherapy and chemotherapy.
All patients were initially evaluated for urinary symptoms, including hematuria, dysuria, and pain on urination. Patients underwent a thorough physical examination, a complete panel of blood tests, abdominal computed tomographic (CT) scanning, cystoscopy with cancer resection/ biopsy, digital subtraction angiography, and more recently, three-dimensional spiral abdominal CT angiography. Bone scan was routinely performed for tumor staging. Before surgery, all patients underwent electrocardiography, chest radiography, and carotid duplex scanning. When indicated, noninvasive cardiac stress testing, either dobutamine echocardiography or the dipyridamol thallium stress test, and pulmonary function tests were performed. Risk factors and associated diseases considered were diabetes, tobacco use, hypertension, hyperlipemia, cardiac status, carotid disease, renal status, and pulmonary status, defined and graded according to the Society for Vascular Surgery/International Society for Cardiovascular Surgery recommended criteria. 2 The day before surgery, patients were admitted to the hospital and received mechanical thorough bowel preparation. All patients were given broad-spectrum antibiotics before surgery.
Operative technique. A standard operative protocol was established in patients with simultaneously occurring invasive TCCB and AAA. AAA was always addressed first. A xipho-pubic incision and transperitoneal approach was performed. Attention was given to retain enough tissue from the aneurysm wall to cover anastomoses and prosthetic graft completely, whenever possible. The retroperitoneum was closed accurately with a double layer of nonabsorbable nylon monofilament material. When the retroperitoneum was inadequate to guarantee a tight seal of the vascular reconstruction, the transmesocolic great epiploon was used as the second layer of sealing.
Access to the bladder was obtained with standard preperitoneal and retroperitoneal incisions, away from vascular access lines. Radical cystoprostatectomy was carried out, followed by pelvic lymphadenectomy to the proximal external and internal iliac arteries. Preaortic and common iliac artery lymphadenectomy was performed only when nodes were macroscopically involved, at the time of vascular reconstruction. In the case of external iliac revascularization, lymphadenectomy in the proximal iliac vessels was also accomplished at the time of vascular reconstruction. Patients underwent either an orthotopic ileal bladder reconstruction (OIBR) according to the vescica ileale padovana (padua ileal neobladder) technique previously described by Pagano et al 3 or an ileal loop urinary diversion (ILUD) according to the Bricker 4 or Wallace 5 technique. The decision on the type of urologic reconstructions was based on the informed patient consensus, the urology team judgment of the patient's ability to manage the neobladder reservoir, and on preoperative and macroscopically tumor staging of less than T 4 . The ileum was carefully surrounded and isolated from the retroperitoneum with surgical wraps. At the end of the reconstruction, prolonged pelvic cavity lavages with antiseptic and antibiotic solutions were repeated and indwelling catheters were placed into the ureters going out of the abdominal wall and into the neobladder through the urethra. A pelvic cavity drainage was positioned through the abdominal wall, and the retroperitoneum was sealed. After surgery, patients were transferred to the intensive care unit.
Postoperative course and follow-up. Patients received a prolonged postoperative antibiotic therapy until all the indwelling catheters were removed. The ureteral catheters were consecutively removed on postoperative days 8 and 9. Radiographic control of the OIBR was performed through the urethra catheter to exclude any urinary leak at postoperative day 10. If any leak was present, the catheter would be left in situ and a new radiographic control scheduled after 10 days. Special attention was directed to detect any sign of infection in the postoperative period.
Patients with a continent OIRB were instructed and trained by physical therapists to void their neobladder reservoir. Pathologic tumor staging was determined according to the tumor nodes metastasis system proposed by the International Union Against Cancer. 6 All patients underwent clinical, laboratory, and ultrasound scan examinations at 1, 4, 8, and 12 months after surgery and every 6 months thereafter. Abdominal CT and bone scans were obtained at 6 and 12 months after surgery and yearly thereafter (Fig 1) . Labeled leukocytes scan (LLS) was performed at 12 months after surgery to detect any silent graft infection.
Study design. For comparison of the results of the simultaneous AAA and TCCB treatment (group A), a prospective study was carried out, with two equal-sized (n ϭ 16) groups of matched control patients undergoing surgery for either AAA (group B) or TCCB (group C) alone. After each simultaneous treatment case, two control patients were selected according to the time of surgery (within 6 months of a simultaneous case), gender, vascular (tube or bifurcated graft), or urologic (VIP or ILUD) reconstruction, respectively, and pathology tumor staging.
Only compliant patients entered the study after informed consensus. Control patients were followed up with the same schedule, except for CT scan and bone scan in group B patients and LLS in group C patients.
The analyzed endpoint was mortality, and confounder variables included common and disease-specific risk factors. Frequency of vascular, urologic, and systemic complications were carefully considered, with special attention to graft infection and tumor recurrence. All data were collected on a spreadsheet database (Excel, Microsoft, Inc, Seattle, Wash), and statistical analysis was performed with the SPSS v10.1 software (SPSS, Inc, Chicago, Ill).
Fisher exact test was used to compare prevalence of graded risk factors among the patient groups. Kaplan-Meier method with log-rank tests was used to estimate and compare survival among the different groups. A two-sided P value of .05 was considered the limit of statistical significance. Cox proportional hazard model was applied to estimate the influence of risk factors (covariates) and groups (forced covariate) on survival. Covariates entered the model with the stepwise forward method (P to enter ϭ .05; P to remove ϭ .10).
RESULTS

Patients characteristics and surgical treatment.
All patients were male. The ages ranged from 61 to 79 years (mean Ϯ standard deviation [SD], 70 Ϯ 5 years) in group A, from 56 to 82 years (mean Ϯ SD, 71 Ϯ 7 years) in group B, and from 47 to 79 years (mean Ϯ SD, 64 Ϯ 9 years) in group C. Table I shows moderate and severe (Society for Vascular Surgery/International Society for Cardiovascular Surgery classification) risk factors in the three groups of patients. For comparison of prevalence of risk factors (including all four grades) among the three patient groups, 4 ϫ 3 contingency tables were generated and analyzed with Fisher exact test. No statistical difference was observed, although the prevalence of moderate renal insufficiency was relevant in group A (P ϭ .08).
Aneurysm size in group A ranged from 4.5 to 8 cm and was greater than 5.5 cm in 10 patients (mean Ϯ SD, 5.5 Ϯ 1 cm). All patients had an infrarenal aneurysm and had open surgical repair. Aortic reconstruction consisted of 10 tube and six aortobiiliac grafts. The sites of distal anastomoses were the common iliac arteries bilaterally in four patients, the right common and left external iliac arteries with exclusion of a left internal iliac aneurysm in one patient, and the right internal and the left external arteries with a graft to right external iliac bypass and exclusion of a left internal iliac aneurysm in one patient. None of the study group patients had an indication to endovascular treatment of AAA in the last 2 years of the study. Reasons for endovascular AAA treatment exclusion included the presence of a short (Ͻ10 mm) proximal neck in two patients, an acute proximal aortic angle of less than 120 degrees in one patient, a bilateral common iliac artery aneurysm extending to the bifurcation in two patients, a tortuous iliac artery (iliac tortuosity index , Ͼ1.6) with more than 50% calcification of the segment length in one patient, and the presence of an accessory renal artery departing from the aneurysm in one patient. One patient underwent a concomitant aortorenal bypass for a greater than 90% right renal artery stenosis, and the previously mentioned patient, reimplantation of the accessory renal artery into the aortic graft. In group B, aortic reconstruction consisted of 10 tube and six bifurcated grafts, all to the common iliac arteries.
In group A, urinary reconstruction included OIBR-VIP in 11 patients and ILUD in five. The urinary diversion was accomplished according to the Wallace 5 (n ϭ 2) or Bricker 4 (n ϭ 3) technique because patients were considered unable to manage the learning process for voiding the urinary reservoir (n ϭ 4) and for staging T4 at surgery (n ϭ 1). According to the research protocol, group C patients underwent the same type of urinary reconstruction, and indications to ILUD were identical. All patients had a histopathologically proven transitional cell carcinoma. Tumor staging is shown in Table II . Nodal involvement (N1) was present only in the T4 patients. No metastases were observed. A concomitant localized prostate carcinoma (ϽT2) was histopathologically proven in five patients of both groups A and C. The prostatectomy was considered curative, and patients did not receive any adjuvant therapy for prostate cancer. The group A average estimated blood loss was higher (1650 Ϯ 550 mL) than in both groups B (850 Ϯ 300 mL) and C (1150 Ϯ 600 mL) but below the total amount of groups B and C collectively considered. The time required to complete the urinary procedure alone (6 Ϯ 1.5 hours) was not considerably increased by the concomitant aneurysm repair (7.4 Ϯ 1.75 hours), with the vascular procedure alone being much faster (2.5 Ϯ 0.75 hours) and with laparotomy and abdominal wall closure common steps to both procedures.
Hospital course. The mean hospital stay was the same in groups A and C and was dependent on TCCB treatment (data not shown). Postoperative complications are shown in Table III . No postoperative mortality was observed. The incidence rates of postoperative systemic complications were 25% in group A, 6.2% in group B, and 25% in group C. Deep vein thrombosis with pulmonary embolism was the most common systemic complication (two patients in group C and one in group A), followed by ventricular arrhythmias (one patient each in groups A and C) and requiring cardioversion in one case.
No graft infection or other vascular complications were seen, whereas the incidence rate of urologic complications was 19% in group A and 25% in group C. Two group A patients with orthotopic bladder reconstructions had a monolateral ureteral obstruction, whereas one group C patient had a bilateral ureteral obstruction, requiring temporary nephrostomy and double J stent placement. One patient in group A had an extensive fluid collection develop in the pelvic cavity in the proximity of the left graft limb anastomosis, with no direct continuity with the prosthesis (Fig 2) . Needle aspiration was performed with CT scan guidance. The fluid proved to be an uncontaminated lymphatic leak on chemical and microbiologic examination. The fluid collection disappeared after 1 month, and no evidence of graft infection was seen on LLS 1 year after surgery.
Two patients in both groups A and C showed a leak of contrast dye at the radiographic control of the neobladder 10 days after surgery. The catheter was left in situ and removed on an outpatient basis 10 or 20 days later, when the following radiographic control showed no dye leakage.
Follow-up. Patients showed no evidence of active or silent graft infection on laboratory or CT and LLS scan examinations. The group A mean follow-up length was 28 months (SD, Ϯ 24 months); 10 patients are still alive without evidence of disease, and six patients died, four of metastatic disease at 6 months (n ϭ 2), at 16 months (n ϭ 1), and at 29 months (n ϭ 1) from surgery and one of myocardial infarction and one of congestive cardiac failure at 2 and 5 months, respectively, after worsening of a preoperative moderate renal insufficiency.
The group B mean follow-up length was 42 months (SD, Ϯ 26 months). Fourteen patients are still alive, and two died, one of lung carcinoma (at 8 months) and one of congestive cardiac failure (at 21 months).
The group C mean follow-up length was 35 months (SD, Ϯ 24 months). Twelve patients are still alive, and four died, three of metastatic disease at 6, 14, and 20 months after surgery and one as a consequence of intestinal occlusion and peritonitis 66 months after surgery. 
Fig 3 shows
Kaplan-Meier survival estimate curves of the three groups. A trend toward increased early mortality in group A was observed. Considering the small sample size and the increased early mortality in group A, the standard error of survival estimate exceeded 10% after 6 months, whereas it exceeded this limit at 34 and 20 months in groups B and C, respectively. Taking into account this limitation, the log-rank test analysis showed no statistical difference of survival among groups (P ϭ .19). Cox proportional hazard model proved no influence of the different groups on survival (P ϭ .49) and no influence of age and risk factors, except for preoperative renal status (P ϭ .015). The presence of preoperative moderate renal insufficiency in two group A patients (Table I ) could explain the decreased survival rate of the simultaneous treatment group in the early follow-up period. The long-term decreased survival rate associated with groups A and C compared with group B is to be ascribed to cancer progression.
One control group C patient underwent nephrouterectomy for a new focus of TCC in the left ureter after 21 months. The patient is still alive after 56 months of cystoprostatectomy and free of recurrence. Anatomic and functional complications were observed in patients with a neobladder reservoir. Ureter-neobladder stenosis was observed in two patients of group A and in three of group C after a period ranging from 4 to 20 months. Patients underwent nephrostomy and temporary double J stent positioning, and two group C patients needed a subsequent terminal ureterectomy and neobladder reimplantation. Two patients of group A were unable to manage the physical maneuvers to void to neobladder. One of them needed the conversion of the VIP reconstruction into ILUD, the other managed to void the neobladder with periodical self-catheterization. One patient in both groups A and C had nocturnal incontinence.
DISCUSSION
The reported incidence rate of concomitant AAAs and abdominal malignant disease is not consistent on published papers, depending on the incidence rate of AAA and malignant diseases considered. Morris and Colquitt 7 found an incidence rate of 12.7% in review of the record of 158 patients with AAA (including nonoperative management) and all histologically proven malignant diseases. With consideration of only the AAA undergoing treatment, Szilagyi, Elliot, and Berguer 1 observed a combined incidence rate of 3.9% with all malignant diseases, whereas the combination with a colorectal malignant disease ranged from 0.5% to 1.4% in different reports. 1, 8, 9 No published data are available on the incidence rate of concomitant AAA and carcinoma of the bladder. In this study, an incidence rate of 3% was observed over a 6-year period. This incidence rate appears to be rather high, considering on the one hand published reports on the incidence rate of AAA and other malignant diseases and on the other that both diseases were surgically managed. The increasing use of more sophisticated CT scan and ultrasonographic devices for preoperative cancer evaluation and AAA detection may in part explain the relatively high incidence rate of the combination observed. Moreover, Padua University Hospital is a national referral center for both complex vascular and urologic diseases, and difficult cases are sent to observation with an increased frequency. Finally, six small aneurysms (4.5 to 5.5 cm of maximal diameter) were surgically addressed in this study, considering both the difficulty of treatment in case of aneurysm enlargement after bladder resection and urinary reconstruction and the low hospital postoperative AAA mortality rate in elective cases (3%; unpublished data). In the series presented by Ginsberg et al, 10 seven patients had a concomitant TCCB and a small aneurysm (diameter, 3.1 to 5.5 cm) that was left in situ. Four patients of this group subsequently needed AAA resection, and at least one other patient died of a ruptured aneurysm.
The major dilemma is represented by the choice of treatment in patients with simultaneously occurring AAA and TCCB. Various therapeutic options are available for the treatment of invasive carcinoma of the bladder. So far, radical cystoprostatectomy with urinary diversion remains a mainstay of treatment for suitable candidates.
Although endovascular treatment is now available for AAA, the conventional method of AAA repair with open surgery still remains the most common and the safer option for treatment. Endovascular AAA graft exclusion may provide the best protection of the prosthetic material from bowel and urinary spill during gastrointestinal and urinary tract manipulation. Unfortunately, not all aneurysm are anatomically suitable for endovascular repair, 11 and despite the improvements of second-generation devices, the incidence rate of graft failure is still significantly higher in endovascular compared with open AAA treatment. 12 In the last 2 years of this study, when the endovascular treatment was introduced at our institution, no patient with concomitant AAA and TCCB was considered suitable for such treatment (52 of 235 patients underwent endovascular AAA graft exclusion in the same period). One patient, not included in this series, previously treated with radical cystoprostatectomy and VIP replacement, had a 5-cm aneurysm develop years later and was successfully treated with endovascular graft exclusion. It should be finally considered that endovascular repair of AAA considerably increases costs of simultaneous treatment of both disease, without reducing postoperative complications, the length of hospital When simultaneous open surgery is performed for both AAA and TCCB, the major concern is possible contamination from gastrointestinal or urinary tract content and, therefore, the best timing of intervention. In a series of eight patients with synchronous aneurysm and invasive bladder cancer, Lierz et al 13 ruled out the simultaneous treatment for the potential of graft infection. The authors treated all their patients with a staged approach, favoring the AAA repair first (four patients) when the aneurysm was greater than 5 cm in diameter because of the postoperative high risk of AAA rupture after a laparotomy performed for a different disease. Swanson et al 14 reported this complication in 10 patients with asymptomatic aneurysms greater than 6 cm in size within 36 days of laparotomy. One prospective study 15 showed that the probability of rupture for an AAA after an unrelated operative procedure averaged 3%.
Subsequent aneurysm repair may also risk ureteral or bowel injury with direct transection or with vascular compromise. On the other hand, as Lierz et al 13 pointed out, repair of the aneurysm before cancer resection potentially allows for further growth and spread of tumor in a patient weakened and possibly immunocompromised by a major procedure. Finally, in the authors' opinion, the risk of graft infection is not completely eliminated if the graft is incompletely healed with protective fibrous capsule and neointima.
Ginsberg et al 10 criticized the two-staged approach because of all the previous considerations and also the difficulties found at the time of the second operation from the obliterative cicatricial destruction of tissue planes in the retroperitoneum. They presented a series of 12 patients undergoing resection of the urologic neoplasm followed by AAA resection with the same anesthesia. Less technical problems were encountered, average blood loss was reduced, and operative time was shorter compared with the staged approach. Furthermore, no graft infections or vascular complications occurred in the follow-up period.
In a recent review, Morris and da Silva 16 questioned the relevance of two previous studies because of lack of treatment protocol. Both retrospective studies did not define the reasons for choosing each of the management options for any particular patients.
In the prospective study presented, a simplified, welldefined, and collaborative treatment was established. A simultaneous approach was proposed to all patients with an indication to open surgery treatment for concomitant AAA and TCCB. The simultaneous intervention was performed by both vascular and urology specialists.
In contrast to the approach proposed by Ginsberg et al 10 , AAA was always resected and replaced first. This approach was favored because the operative field is not obstructed by the urinary bladder reconstruction, which lays anterior to the aortic bifurcation, making the AAA resection and graft anastomoses more difficult and at risk of contamination. On the contrary, the vascular graft carefully surrounded and sealed by the aneurysmal wall and retroperitonel tissue does not encumber the surgical field during cystoprostatectomy and bladder reconstruction. The retroperitoneum is carefully closed before the urology procedure to avoid working on the same surgical dissection planes as much as possible. Any vascular intestinal ischemia can also be verified before the urologic reconstruction.
The choice of control group patients in this study may be criticized. Comparison with a staged treatment group of patients would have been more appropriate, and for this reason, this study may be considered like a review of the simultaneous approach more than a comparison with a true alternative treatment. However, the staged approach was not considered a fair choice for patients with coexisting diseases for the reasons previously explained, and given the rarity of the diseases association, the small sample size of the two groups would have not been adequate for any valuable comparison. The selected control patients were seen and underwent surgery for either one of the two diseases simultaneously treated in patients with coexisting diseases and were expected to have at least similar or better results than the study group patients. Therefore, the underlying hypothesis of the study was that results of the simultaneous approach to coexisting diseases were not significantly worse than those of the treatment of the single-presenting disease. Despite the incidence rate of the coexisting diseases being rather high in this study, survival analysis was hampered by the limited sample size (16 cases over 6 years) and the slightly increased mortality rate observed in the study group in the early follow-up period. Nevertheless, some valuable conclusions can be drawn from the study results.
No perioperative mortality was observed. Systemic and urologic complications were similar in patients undergoing simultaneous surgical treatment of coexisting AAA and TCCB and surgery for bladder cancer alone. Concomitant TCCB and AAA treatment did not increase the risk of vascular graft infection and other vascular complications. Preoperative renal insufficiency may represent a particular risk for increased short-term mortality in patients undergoing the simultaneous treatment, and special attention should be given to renal preoperative function evaluation and perioperative treatment. Long-term survival of simultaneously treated patients is mainly dependent on cancer progression.
This study shows that the simultaneous surgical approach to coexisting AAA and TCCB may represent a suitable choice of treatment in specialized centers. Whenever anatomic characteristics are suitable, endovascular therapy of AAA in patients with coexisting TCCB is an appealing alternative to simultaneous surgery.
